Literature DB >> 8522275

Spontaneous adult height in idiopathic short stature.

M B Ranke1, M L Grauer, K Kistner, W F Blum, H A Wollmann.   

Abstract

Two hundred and thirty-six patients with idiopathic short stature (ISS) (184 m, 52 f) who presented at a mean age of 12.2 (range 2.8-17.5) years, a mean height of -2.16 standard deviation score (SDS), a mean target height (THT) of -0.27 SDS (m = f), were reinvestigated at a mean age of 20.5 (range 18-24) years. 182(142 m, 37 f) (67%) had reached normal adult height (AHT) while 54 (39 m, 15 f) (23%) had not. However, only 23 (17 m, 6 f) did not reach a height within their familial target. Patients were subdivided into 2 groups according to deviation from familial height target: 60(44 m, 16 f) were considered adequate for their families (group 1), while 176 (140 m, 39 f) were smaller (group 2). Children in group 1 were younger and bone age (BA) was less retarded. Patients in group 1 reached their THT, this was not the case in group 2. Young age, low THT and low predicted adult height (PAH) at presentation were the factors associated with poor stratural outcome, but AHT could not be predicted in individuals. In boys, PAH (Bayley-Pinneau) (0.0 SDS) exceeded AHT (-0.7 SDS), in girls, both were almost identical (-0.79, -0.77 SDS). Since most children with ISS reach an AHT within the normal range, attempts to improve AHT by means of growth-promoting therapies appear to be justified only in a minority of selected patients with ISS. Methods to improve the accuracy of individual height prognoses are needed.

Entities:  

Mesh:

Year:  1995        PMID: 8522275     DOI: 10.1159/000184616

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  10 in total

Review 1.  The use of somatropin (recombinant growth hormone) in children of short stature.

Authors:  Ameeta Mehta; Peter C Hindmarsh
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

2.  Spontaneous growth in idiopathic short stature. European Study Group.

Authors:  L T Rekers-Mombarg; J M Wit; G G Massa; M B Ranke; J M Buckler; O Butenandt; J L Chaussain; H Frisch; E Leiberman
Journal:  Arch Dis Child       Date:  1996-09       Impact factor: 3.791

Review 3.  A risk-benefit assessment of growth hormone use in children.

Authors:  S L Blethen; M H MacGillivray
Journal:  Drug Saf       Date:  1997-11       Impact factor: 5.606

4.  A Novel Method for Adult Height Prediction in Children With Idiopathic Short Stature Derived From a German-Dutch Cohort.

Authors:  Werner F Blum; Michael B Ranke; Eberhard Keller; Alexandra Keller; Sandra Barth; Christiaan de Bruin; Stefan A Wudy; Jan M Wit
Journal:  J Endocr Soc       Date:  2022-05-06

5.  Managing idiopathic short stature: role of somatropin (rDNA origin) for injection.

Authors:  J Paul Frindik; Stephen F Kemp
Journal:  Biologics       Date:  2010-06-24

Review 6.  Treatment of children and adolescents with idiopathic short stature.

Authors:  Michael B Ranke
Journal:  Nat Rev Endocrinol       Date:  2013-04-23       Impact factor: 43.330

7.  A randomized pilot trial of growth hormone with anastrozole versus growth hormone alone, starting at the very end of puberty in adolescents with idiopathic short stature.

Authors:  Anya Rothenbuhler; Agnès Linglart; Pierre Bougnères
Journal:  Int J Pediatr Endocrinol       Date:  2015-02-16

8.  Causes of short stature identified in children presenting at a tertiary care hospital in Multan Pakistan.

Authors:  Muhammad Waqar Rabbani; Waqas Imran Khan; Ahmad Bilal Afzal; Waqas Rabbani
Journal:  Pak J Med Sci       Date:  2013-01       Impact factor: 1.088

9.  Causes of short stature in Pakistani children found at an Endocrine Center.

Authors:  Ali Jawa; Syed Hunain Riaz; Muhammad Zaman Khan Assir; Bahjat Afreen; Amna Riaz; Javed Akram
Journal:  Pak J Med Sci       Date:  2016 Nov-Dec       Impact factor: 1.088

10.  Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit.

Authors:  Juan F Sotos; Naomi J Tokar
Journal:  Int J Pediatr Endocrinol       Date:  2014-07-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.